Ali A Asadi-Pooya1, Gregory R Stewart2, Daniel J Abrams3, Ashwini Sharan4. 1. Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: aliasadipooya@yahoo.com. 2. Alchemy Neuroscience, Hanover, Massachusetts, USA. 3. Cerebral Therapeutics, Denver, Colorado, USA. 4. Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Cerebral Therapeutics, Denver, Colorado, USA.
Abstract
OBJECTIVE: We reviewed data on the epidemiology of epilepsy in the United States and estimated the prevalence and incidence of drug-resistant temporal lobe epilepsy (TLE) due to hippocampal sclerosis (HS) based on extrapolation from the available data drawn from the literature. METHODS: We searched the electronic database PubMed on December 14, 2016, using the following search terms in the title: "epilepsy" OR "temporal lobe" OR "hippocampal sclerosis" AND "epidemiology" OR "prevalence" OR "incidence." Relevant original studies were included. We also reviewed several previous systematic reviews, meta-analyses, and their references. RESULTS: We concluded that the estimated current U.S. prevalence of drug-resistant HS-TLE is 0.51-0.66 cases per 1000 people, and the estimated U.S. incidence is 3.1-3.4 cases per 100,000 people per year. Based on a U.S. population of 324 million, we estimate that as many as 143,000-191,000 U.S. patients still suffer from drug-resistant HS-TLE and are in need of surgery or other therapeutic options. CONCLUSIONS: Although full scale epidemiologic studies on drug-resistant HS-TLE are needed, several observational studies allow adequate estimates of the range for the incidence and prevalence of this condition. Given the morbidity and mortality associated with poorly controlled seizures, this relatively large and growing patient population is a matter of concern. Considering the variety of treatment options that are available or in the pipeline to treat drug-resistant epilepsy, future efforts should focus on advocating for early referral of patients with drug-resistant HS-TLE for more comprehensive epilepsy management.
OBJECTIVE: We reviewed data on the epidemiology of epilepsy in the United States and estimated the prevalence and incidence of drug-resistant temporal lobe epilepsy (TLE) due to hippocampal sclerosis (HS) based on extrapolation from the available data drawn from the literature. METHODS: We searched the electronic database PubMed on December 14, 2016, using the following search terms in the title: "epilepsy" OR "temporal lobe" OR "hippocampal sclerosis" AND "epidemiology" OR "prevalence" OR "incidence." Relevant original studies were included. We also reviewed several previous systematic reviews, meta-analyses, and their references. RESULTS: We concluded that the estimated current U.S. prevalence of drug-resistant HS-TLE is 0.51-0.66 cases per 1000 people, and the estimated U.S. incidence is 3.1-3.4 cases per 100,000 people per year. Based on a U.S. population of 324 million, we estimate that as many as 143,000-191,000 U.S. patients still suffer from drug-resistant HS-TLE and are in need of surgery or other therapeutic options. CONCLUSIONS: Although full scale epidemiologic studies on drug-resistant HS-TLE are needed, several observational studies allow adequate estimates of the range for the incidence and prevalence of this condition. Given the morbidity and mortality associated with poorly controlled seizures, this relatively large and growing patient population is a matter of concern. Considering the variety of treatment options that are available or in the pipeline to treat drug-resistant epilepsy, future efforts should focus on advocating for early referral of patients with drug-resistant HS-TLE for more comprehensive epilepsy management.
Authors: João Paulo Sant Ana Santos de Souza; Gabriel Ayub; Pamela Castro Pereira; José Paulo Cabral Vasconcellos; Clarissa Yasuda; Andrei Fernandes Joaquim; Helder Tedeschi; Brunno Machado Campos; Fernando Cendes; Enrico Ghizoni Journal: Neuroradiology Date: 2019-09-07 Impact factor: 2.804
Authors: Sarah Gourmaud; Haochang Shou; David J Irwin; Kimberly Sansalone; Leah M Jacobs; Timothy H Lucas; Eric D Marsh; Kathryn A Davis; Frances E Jensen; Delia M Talos Journal: Brain Date: 2020-01-01 Impact factor: 13.501
Authors: Renata Parissi Buainain; Matheus Negri Boschiero; Bruno Camporeze; Paulo Henrique Pires de Aguiar; Fernando Augusto Lima Marson; Manoela Marques Ortega Journal: Cell Mol Neurobiol Date: 2021-03-05 Impact factor: 5.046
Authors: Kristin E Wills; Hernán F J González; Graham W Johnson; Kevin F Haas; Victoria L Morgan; Saramati Narasimhan; Dario J Englot Journal: Epilepsy Behav Date: 2020-12-15 Impact factor: 2.937